Literature DB >> 6433140

Feasibility of willingness-to-pay measurement in chronic arthritis.

M S Thompson, J L Read, M Liang.   

Abstract

Quantification of nonmonetary aspects of disease is a major challenge for economic analysts. Using the amounts of money recipients are willing to pay for nonmonetary benefits has theoretical appeal, but it has proven difficult to implement. Difficulties encountered include noncomprehension by subjects, misrepresentation of preferences, extraneous determinants of answers, and ethical concerns. In a preliminary exploration of feasibility, 184 patients with osteoarthritis and rheumatoid arthritis were asked their willingness to pay (WTP) for hypothetical complete cure. With minimal pressure put on the patients to respond, 27 percent gave plausible answers. People with more schooling, with paid employment, or who were having more treatments for their arthritis were more likely to respond. Patients were willing on average to pay 17 percent of family income for arthritis cure. Methods for measuring WTP are being strengthened and may soon play an important role in health services research.

Entities:  

Mesh:

Year:  1984        PMID: 6433140     DOI: 10.1177/0272989X8400400207

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  6 in total

1.  Defining monetary values for quality of life improvements: an exploratory study.

Authors:  Jean Lachaine; Claudine Laurier; André-Pierre Contandriopoulos
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

2.  Economic evaluation in healthcare. A brief history and future directions.

Authors:  K Blumenschein; M Johannesson
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

3.  Willingness to pay and accept risks to cure chronic disease.

Authors:  M S Thompson
Journal:  Am J Public Health       Date:  1986-04       Impact factor: 9.308

Review 4.  Cost-effective policies for cervical cancer screening. An international review.

Authors:  M C Fahs; S B Plichta; J S Mandelblatt
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

5.  Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis.

Authors:  Patrick W Sullivan; Sheryl L Follin; Michael B Nichol
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 6.  The impact of economic evaluation on quality management in spine surgery.

Authors:  Norbert Boos
Journal:  Eur Spine J       Date:  2009-04-01       Impact factor: 3.134

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.